| Completed | Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region NCT03995862 | Centre Hospitalier Annecy Genevois | — |
| Completed | Linkage of Transgender Individuals to PrEP NCT03191474 | University of California, San Diego | N/A |
| Completed | Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individua NCT03086200 | University of California, San Diego | N/A |
| Completed | Pre-exposure Prophylaxis Accessibility Research and Evaluation 2 NCT02125773 | University of California, San Diego | N/A |
| Completed | CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM NCT01761643 | University of California, San Diego | Phase 4 |
| Completed | Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HI NCT01418235 | HIV Vaccine Trials Network | Phase 1 |
| Terminated | Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials NCT00789789 | ANRS, Emerging Infectious Diseases | — |
| Completed | Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm NCT00076817 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes NCT00076232 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Voluntee NCT00121121 | French National Agency for Research on AIDS and Viral Hepatitis | Phase 1 |
| Completed | Botanical/Drug Interactions in HIV: Glucuronidation NCT00065741 | National Center for Complementary and Integrative Health (NCCIH) | Phase 1 |
| Completed | Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients NCT00055237 | National Cancer Institute (NCI) | Phase 2 |
| Completed | HIV-1 Vaccine Test in Uninfected Adult Volunteers NCT00047931 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | HIV Incidence and Participation Retention in Pune, India NCT00028119 | HIV Prevention Trials Network | — |
| Completed | Screening Protocol for HIV Vaccine Studies NCT00031304 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | HIV-1 Vaccine Test in Uninfected Adult Volunteers NCT00009685 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Peer Mentors for Adolescents in HIV Affected Families NCT00056953 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 |
| Completed | Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand NCT00006327 | VaxGen | Phase 3 |
| Completed | A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection NCT00004579 | Walter Reed Army Institute of Research (WRAIR) | Phase 1 |
| Completed | Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection NCT00002441 | VaxGen | Phase 3 |
| Completed | HIV Prevention Preparedness Study NCT00048282 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Study of Immune System Activity in Healthy Adults NCT00014053 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Study to Test the Safety of Three Experimental HIV Vaccines NCT00000946 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV NCT00000868 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study of Male Rectal Samples in Preparation for Future Rectal Microbicide Trials NCT00075062 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study o NCT00000777 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Withdrawn | Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/H NCT00001046 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59 NCT00000632 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy NCT00002204 | Chiron Corporation | Phase 1 |
| Completed | A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV- NCT00001043 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission NCT00053612 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Unknown | HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults NCT00013572 | Walter Reed Army Institute of Research (WRAIR) | Phase 1 |
| Completed | A Study of GENEVAX-HIV, a Possible Vaccine NCT00002232 | Wyeth-Lederle Vaccines | Phase 1 |
| Completed | Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults NCT00027261 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Blood Test to Look at Cells of the Immune System in Healthy Children NCT00001109 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs NCT00017758 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Carotid Artery Thickness in HIV Infected and Uninfected Adults NCT00007319 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru NCT00023582 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers NCT00002231 | Wyeth-Lederle Vaccines | Phase 1 |
| Completed | A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety NCT00000972 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Bo NCT00000774 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Withdrawn | Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women NCT00000809 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers NCT00000879 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Withdrawn | Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia NCT00078182 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 / Phase 3 |
| Completed | Long-Term Effects of HIV Exposure and Infection in Children NCT00006304 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa NCT00006298 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | ALVAC-HIV vCP1452 Alone and Combined With MN rgp120 NCT00011037 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunt NCT00001136 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |